Advancement in the development of mRNA ‐based vaccines for respiratory viruses
Immunology · 2024
DOI: 10.1111/imm.13844 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, 2024. Verfasst von Tays Troncoso-Bravo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Millennium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. Hauptthemen laut MEDLINE: mRNA Vaccines, Respiratory Tract Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 133 Literaturangaben. Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico, Agencia Nacional de Investigación y Desarrollo - Millenium Institute on Immunology and Immunotherapy, Agencia Nacional de Investigación y Desarrollo.
Abstract (Originalsprache)
Acute respiratory infections are the leading cause of death and illness in children under 5 years old and represent a significant burden in older adults. Primarily caused by viruses infecting the lower respiratory tract, symptoms include cough, congestion, and low‐grade fever, potentially leading to bronchiolitis and pneumonia. Messenger ribonucleic acid (mRNA)‐based vaccines are biopharmaceutical formulations that employ mRNA molecules to induce specific immune responses, facilitating the expression of viral or bacterial antigens and promoting immunization against infectious diseases. Notably, this technology had significant relevance during the COVID‐19 pandemic, as these formulations helped to limit SARS‐CoV‐2 virus infections, hospitalizations, and deaths. Importantly, mRNA vaccines promise to be implemented as new alternatives for fighting other respiratory viruses, such as influenza, human respiratory syncytial virus, and human metapneumovirus. This review article analyzes mRNA‐based vaccines' main contributions, perspectives, challenges, and implications against respiratory viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Millennium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Departamento de Ingeniería Química y Bioprocesos, Facultad de Ingeniería, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Laboratory of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Clinical Research Unit, Special Unit for Biomedical Research and Education (SUBRE), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
ORCID-Profile: Pablo A González, Susan M Bueno, Alexis M Kalergis
Förderung
- Fondo Nacional de Desarrollo Científico y Tecnológico
- Agencia Nacional de Investigación y Desarrollo - Millenium Institute on Immunology and Immunotherapy
- Agencia Nacional de Investigación y Desarrollo
- Biomedical Research Consortium-Chile
Zitieren
APA
Troncoso-Bravo, T., Ramírez, M. A., Loaiza, R. A., Román-Cárdenas, C., Papazisis, G., Garrido, D., González, P. A., Bueno, S. M., & Kalergis, A. M. (2024). Advancement in the development of mRNA ‐based vaccines for respiratory viruses. Immunology. https://doi.org/10.1111/imm.13844
Vancouver
Troncoso-Bravo T, Ramírez MA, Loaiza RA, Román-Cárdenas C, Papazisis G, Garrido D, et al. Advancement in the development of mRNA ‐based vaccines for respiratory viruses. Immunology. 2024. doi:10.1111/imm.13844
BibTeX
@article{TroncosoBravo2024,
author = {Troncoso-Bravo, Tays and Ramírez, Mario A and Loaiza, Ricardo A and Román-Cárdenas, Carolina and Papazisis, Georgios and Garrido, Daniel and González, Pablo A and Bueno, Susan M and Kalergis, Alexis M},
title = {Advancement in the development of mRNA ‐based vaccines for respiratory viruses},
journal = {Immunology},
year = {2024},
doi = {10.1111/imm.13844}
}
EUVIMED